GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Pre-Tax Income

Apollon Formularies (AQSE:APOL) Pre-Tax Income : £-0.76 Mil (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Apollon Formularies's pretax income for the six months ended in Jun. 2023 was £-0.76 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.76 Mil. Apollon Formularies's pretax margin was -1,591.67%.

During the past 11 years, Apollon Formularies's highest Pretax Margin was -1.22%. The lowest was -41100.00%. And the median was -745.92%.


Apollon Formularies Pre-Tax Income Historical Data

The historical data trend for Apollon Formularies's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Pre-Tax Income Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.32 -2.18 -0.50 -2.53

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -1.70 -0.84 -0.21 -0.76

Competitive Comparison of Apollon Formularies's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Pre-Tax Income falls into.



Apollon Formularies Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Apollon Formularies's Pretax Income for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.762+0+-0.004+0+-1.765
=-2.53

Apollon Formularies's Pretax Income for the quarter that ended in Jun. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.403+0+0+0.004+-0.365
=-0.76

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Pre-Tax Income Explanation

Apollon Formularies's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.764/0.048
=-1,591.67%

During the past 11 years, Apollon Formularies's highest Pretax Margin was -1.22%. The lowest was -41100.00%. And the median was -745.92%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

5 Stocks Trading Near Their Historical Low P/S Ratios

By Holly LaFon Holly LaFon 04-11-2012

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

FPA Capital Fund Comments on Apollo Education Group

By Holly LaFon Holly LaFon 02-09-2016

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013